|
Market Closed -
Nasdaq
01:30:00 04/09/2026 am IST
|
5-day change | 1st Jan Change | ||
| 89.71 USD | +0.02% |
|
+0.47% | +35.17% |
| 25/08 | Dexcom Insider Sold Shares Worth $2,408,242, According to a Recent SEC Filing | MT |
| 13/08 | Citigroup Adjusts Price Target on DexCom to $105 From $88, Maintains Buy Rating | MT |
Company Valuation: DexCom, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 52,042 | 43,740 | 47,945 | 30,377 | 25,885 | 33,853 | - | - |
| Change | - | -15.95% | 9.61% | -36.64% | -14.79% | 30.78% | - | - |
| Enterprise Value (EV) 1 | 52,692 | 45,068 | 49,813 | 31,073 | 26,209 | 33,092 | 32,792 | 31,977 |
| Change | - | -14.47% | 10.53% | -37.62% | -15.65% | 26.26% | -0.91% | -2.49% |
| P/E | 346x | 138x | 95.5x | 54.8x | 31.8x | 36x | 30.2x | 24.9x |
| PBR | 23.1x | 20.5x | 23.1x | 15.1x | 9.3x | 11.9x | 9.93x | 7.64x |
| PEG | - | 1x | 1.6x | 5.94x | 0.7x | 1.9x | 1.6x | 1.2x |
| Capitalization / Revenue | 21.3x | 15x | 13.2x | 7.53x | 5.55x | 6.47x | 5.84x | 5.24x |
| EV / Revenue | 21.5x | 15.5x | 13.8x | 7.7x | 5.62x | 6.33x | 5.65x | 4.95x |
| EV / EBITDA | 111x | 60x | 49.1x | 28.1x | 19.4x | 19.9x | 17.1x | 14.4x |
| EV / EBIT | 142x | 92.9x | 69.3x | 41x | 27x | 26.5x | 22.7x | 18.6x |
| EV / FCF | 989x | 148x | 97.3x | 49.3x | 24.3x | 32.4x | 26.9x | 21.8x |
| FCF Yield | 0.1% | 0.68% | 1.03% | 2.03% | 4.11% | 3.09% | 3.72% | 4.59% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | 0.3875 | 0.82 | 1.3 | 1.42 | 2.09 | 2.495 | 2.969 | 3.596 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 2,448 | 2,910 | 3,622 | 4,033 | 4,662 | 5,230 | 5,800 | 6,461 |
| EBITDA 1 | 472.7 | 751.6 | 1,014 | 1,105 | 1,349 | 1,666 | 1,920 | 2,218 |
| EBIT 1 | 370.7 | 485.1 | 718.6 | 757.1 | 969.3 | 1,247 | 1,445 | 1,722 |
| Net income 1 | 154.7 | 341.2 | 541.5 | 576.2 | 836.3 | 974.4 | 1,149 | 1,409 |
| Net Debt 1 | 650.1 | 1,328 | 1,868 | 695.9 | 323.2 | -761.1 | -1,061 | -1,877 |
| Reference price 2 | 134.24 | 113.24 | 124.09 | 77.77 | 66.37 | 89.71 | 89.71 | 89.71 |
| Nbr of stocks (in thousands) | 3,87,688 | 3,86,258 | 3,86,374 | 3,90,595 | 3,90,016 | 3,77,361 | - | - |
| Announcement Date | 10/02/22 | 09/02/23 | 08/02/24 | 13/02/25 | 12/02/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 35.96x | 6.33x | 19.86x | -.--% | 3.39TCr | |
| 31.21x | 4.22x | 16.21x | 2.36% | 19TCr | |
| 19.69x | 3.59x | 12.84x | 3.05% | 12TCr | |
| 18.47x | 0.21x | 13.42x | 0.71% | 6.44TCr | |
| 29.98x | 7.39x | 19.09x | 1.33% | 5.26TCr | |
| 36.16x | 3.47x | 11.9x | 2.09% | 5.11TCr | |
| 47.24x | 1.35x | 12.52x | 0.2% | 3.21TCr | |
| 39.97x | 7x | 25.11x | 0.26% | 2.41TCr | |
| 18.39x | 2.93x | 10.38x | 1.5% | 2.34TCr | |
| 24.43x | 3.68x | 12.95x | 1.17% | 2.21TCr | |
| Average | 30.15x | 4.02x | 15.43x | 1.27% | 6.11TCr | |
| Weighted average by Cap. | 28.64x | 3.89x | 15.16x | 1.81% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- DXCM Stock
- Valuation DexCom, Inc.
Select your edition
All financial news and data tailored to specific country editions
